EP4656737A1 — Biomarker composition for liver disease diagnosis and pharmaceutical composition for treatment containing lrg1 protein or coding gene therefor
Assigned to Industry Academic Cooperation Foundation of KNU · Expires 2025-12-03 · 0y expired
What this patent protects
The present invention relates to a biomarker composition for the diagnosis of liver diseases. It has been confirmed that Lrgl increases in cases of liver fibrosis, indicating that Lrgl can be utilized for the diagnosis of liver diseases, including liver fibrosis. Furthermore, the…
USPTO Abstract
The present invention relates to a biomarker composition for the diagnosis of liver diseases. It has been confirmed that Lrgl increases in cases of liver fibrosis, indicating that Lrgl can be utilized for the diagnosis of liver diseases, including liver fibrosis. Furthermore, the potential of Lrgl as a therapeutic target for liver diseases has been identified, allowing its use in the prevention or treatment of liver diseases.
Drugs covered by this patent
- Zokinvy (LONAFARNIB) · Sentynl Theraps Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.